neovascularization, its performance in GBM therapy is not satisfactory. 14, 15 For newly diagnosed GBM, two multi-centre, randomized phase III clinical trials (the AVAglio study and the Radiation Therapy and Oncology Group [RTOG] 0825 trial) showed benefits only in progression-free survival (PFS), not in overall survival (OS). [16] [17] [18] These results suggest that not all patients benefit from anti-angiogenic therapy, and furthermore, there are no definitive biomarkers predicting the benefits of anti-angiogenic therapy in GBM. Therefore, finding biomarkers that can identify patients who are more likely to benefit from anti-angiogenic treatment is very important.
This article will summarize potential biomarkers that can predict the benefits of anti-angiogenic treatment for GBM and provide diagnostic information and will describe our expectations for the near future.
| B I OMARK ER S FOR B E VACIZUMAB
In 1993, bevacizumab (BEV) was synthesized for the first time. 19 As an anti-angiogenic monoclonal antibody, BEV can slow the growth of new blood vessels in tumours by inhibiting VEGF-A. 20 As discussed above, two phase III trials combining BEV with radiotherapy and chemotherapy displayed no OS benefit. 17 Molecular markers that can predict the effect of BEV on GBM therapy are urgently needed.
| Prognostic value of molecular classification for the effect of anti-angiogenic targeted drugs

| Isocitrate dehydrogenase 1 wild-type proneural subtype
Better clarification of the roles of key genes has helped to classify gliomas into different molecular subtypes based on their molecular markers, providing new ideas for the clinical diagnosis and prognosis of gliomas.
Due to the heterogeneity of gliomas, patient outcome may vary across different subtypes. For example, among the four GBM subtypes in Phillips's classification, 21 the proneural subtype was originally considered the subtype with the longest OS, but this result was later attributed to a small subset of patients with an isocitrate dehydrogenase 1 (IDH1) mutation. 22 In addition, IDH1 wild-type proneural tumours had the worst prognosis among all GBM subtypes in the placebo arm.
Based on these facts, a retrospective study of the AVAglio trial compared the effects of BEV treatment on proneural GBM and three other subtypes of GBM (including only wild-type IDH1). 16, 23 The results
showed beneficial effects on PFS in the proneural (9. 
| Matrix metalloproteinases
Matrix metalloproteinases (MMPs), also known as matrixins, are calcium-dependent zinc-containing endopeptidases, which play major roles in cell behaviours such as proliferation, migration, differentiation, angiogenesis, apoptosis and host defence. 28 A report published in Neuro-Oncology 2013 showed the predictive value of serum matrix metalloproteinase 2 (MMP2) levels by investigating the relationship between recurrent high-grade glioma (HGG) and serum MMP2 levels (Table 1) . 29 In the initial cohort (cohort 1), patients treated with BEV and irinotecan were divided into two groups according to their response. Most patients with increased serum MMP2 levels were found to be responders (10/12). Subsequent single-variant analysis showed that the serum MMP2 level was significantly associated with PFS and OS. In addition, matrix metalloproteinase 9 (MMP9) might be associated with PFS and OS. To verify this hypothesis, the author divided cohort 2 according to their MMP2 and MMP9 levels. The results revealed that the median PFS and OS for patients with increased serum MMP2 levels were 7.1 and 11.8 months, respectively, and were significantly higher than the corresponding values in patients with low serum MMP2 levels (4.2 and 5.9 months respectively). However, no OS/PFS benefit was observed in the MMP9
group. Similar findings were observed in the GBM patients. However, in patients treated with cytotoxic agents or immunotherapy instead of anti-angiogenic agents, low serum MMP2 levels were associated with better OS (P = 0.66).
A study published in 2014 found that not only MMP2 serum levels but also the combination of serum MMP9 and MMP2 levels could predict BEV response and showed an association with OS in newly diagnosed GBM patients. 16 Based on this research, Chinot et al performed post-hoc evaluation of the baseline serum MMP9
and MMP2 levels in 577 of 921 tumour samples in the AVAglio trial (BEV group, n = 283; placebo group, n = 294). 30 was a relationship between the MMP9 level and OS (P = 0.03).
However, no predictive or prognostic value of MMP2 levels was shown in this study.
| MicroRNA
MicroRNA expression plays an important role in the tumourigenesis, infiltration and deterioration of glioma. The role of microRNA in glioma physiology and its high stability in clinical samples indicate that microRNA may be a primary candidate as a predictive biomarker. 31 Many researchers have sought to determine the predictive value of microRNA.
A 2016 study used TCGA data to investigate the relationship between microRNA expression and the effect of BEV treatment in GBM patients. 32 The study identified and validated the predictive value of an 8-microRNA profile for the therapeutic effect of BEV.
The responder group was defined as having a response score >0, while the non-responder group had a score <0.
The defined cut-off response score of 0 was used to separate a total of 37 test set samples into two groups, responders and non-responders. The OS of the responder group was significantly longer than that of the non-responder group (mOS 21 vs 15 months, HR = 0.34, 95% CI = 0.11-1.01, P = 0.026). The researchers also calculated the response scores for all 473 GBM patients in the TCGA database (treated with various regimens excluding BEV) and found no significant difference between the responder group and the non-responder group (Table 1) . These results indicated that the predictive value of the 8-microRNA algorithm was BEV specific. Unfortunately, the 8-microRNA spectrum did not significantly correlate with PFS and the validation of this assay will require assessment in larger cohorts.
In addition, recent evidence has shown the predictive value of microRNA-21 and microRNA-10b. 33 A meta-analysis of previous 
| Peripheral neutrophil count
Preclinical studies have shown that neutrophils may promote tumour neovascularization. Therefore, a high neutrophil count was hypothesized to be associated with a better response to anti-VEGF therapy. 35 To address this possibility, researchers investigated the predictive role of the peripheral blood neutrophil count before BEV treatment on the efficacy of BEV. (Table 1) . Interestingly, the predictive value of the neutrophil count disappeared after BEV treatment: in other words, BEV was able to compensate for the deleterious effect of a high neutrophil count.
| Angiotensinogen and human leucocyte antigen class II
Angiotensinogen (AGT) and all components of the renin-angiotensin system are expressed in GBM. 37 In addition, increased AGT expression was associated with a higher level of vascular proliferation.
In a study published in 2016, gene expression in tumour tissue was analysed in recurrent GBM (rGBM) patients who were responsive to BEV/irinotecan combination therapy. The analysis was conducted using a platform covering 800 genes to identify predictive biomarkers for BEV response in rGBM patients. Multivariant logistic analysis and Cox regression analysis were also performed for candidate genes with possible predictive value. 38 The results showed that 82 of 158 patients were responsive to treatment. In addition, the Table 1 ).
In addition to AGT, single-variant analysis showed that high gene expression of human leukocyte antigen (HLA) class II was significantly associated with prolonged OS (P = 0.03) and better treatment response (twofold increase in HLA class II: OR = 1.22, 95% CI = 1.01-1.47, P = 0.04) but was not associated with PFS (P = 0.16).
However, this association was not detected by multivariant analysis.
| Predictive value of PTEN integrity
PTEN deficiency is a precondition for the specific expression of VEGF-2 in gliomas. A 2014 study investigated the possibility of using PTEN to predict the effect of BEV treatment. 39 (Table 1 ). However, this study was limited by its small sample size and its results should be further verified by larger studies.
| Predictive value of hypertension after BEV treatment
VEGF, via binding to VEGF receptor (VEGFR), can stimulate endothelial cells to produce NO, which leads to vessel dilatation and a decrease in arterial blood pressure. BEV can inhibit VEGF signalling and indirectly lead to an immediate increase in blood pressure.
Therefore, hypertension can give indirect information about the effect of BEV and might be a prognostic factor for treatment.
An article published in Cancer 2014 reported the interesting finding that drug-induced hypertension might have predictive value for the effect of BEV treatment in rGBM patients. 40 A total of 82 rGBM patients who received BEV therapy after standard treatment were included in the study. Patients with no history of hypertension were divided into two groups: patients with post-BEV treatment systolic pressure >140 mm Hg or diastolic pressure >90 mm Hg were placed in the hypertensive group and others in the normotensive group. The PFS and OS for the two groups showed a marked difference (PFS: hypertensive 6.7 vs normotensive 2.5 months, P < 0.001; OS: hypertensive 11.7 vs normotensive 4.9 months, P < 0.001) ( Table 1 ). This result suggested that drug-induced hypertension was associated with better outcome after BEV treatment, which was supported by the results from other malignancies. 
| B I OMARK ER S FOR CILENG ITIDE
| B I OMARK ER S FOR ENZ A S TAURIN
Enzastaurin, a cyclic bisindole maleimide, is an oral serine/threonine kinase inhibitor that specifically inhibits the protein kinase C and phosphatidylinositol 3-kinase and protein kinase B (PI3K/AKT) signalling pathways, leading to cell apoptosis, the inhibition of cell proliferation and anti-tumour-induced angiogenesis. 45, 46 In 2006, the EU and FDA approved enzastaurin for the treatment of GBM. 47 In 2010, a phase I/II clinical trial showed that enzastaurin exhibited some anti-tumour activity against recurrent gliomas, but it cannot be used for monotherapy. Fortunately, as imaging development and research continue, the use of imaging markers, such as relative cerebral blood volume, K trans and others, to predict the effect of treatment is also under development.
Some low-cost biopsies can also address this problem through the analysis of markers in the circulating blood, the urine or a combination. In addition to the problems involving markers themselves, problems in the research methods cannot be ignored. The current studies are all retrospective studies of well-designed clinical trials, lacking independent validation. In addition, more attention should be paid to molecular markers, such as peripheral blood neutrophils and plasma MMPs. Baselines must be determined to obtain unified criteria to guide follow-up studies.
In addition to the above problems, it is also important to account for the differences among studies. The predictive weights of different markers may be different, so a formula must be established to determine the weights of different markers.
In conclusion, although many problems remain, the use of molecular biomarkers can prolong the OS of patients and reduce their financial burden. We should pay more attention to the study of biomarkers and establish a predictive formula.
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